Laboratory Studies Into the Pathology of Leukaemia
Trial Snapshot
- Phase
- Not Applicable
- Enrollment
- 500
- Locations
- 1
- Primary Endpoint
- Pathology of Leukaemia cells
Study Overview
Brief Summary
Ongoing laboratory work into the pathology of Leukaemia:
Detailed Description
The investigators will test AML samples sent to the diagnostic laboratory from participants with newly diagnosed or relapsed/refractory AML. Samples will be sent from district general hospitals and teaching hospitals.
Results will be returned to referring clinicians in the same way investigators currently return results for samples sent for standard tests. The service will be advertised through the Royal Marsden Website with visibility to both participants and HCPs). The investigators will also inform all the clinicians involved in the AML working party (Dr Taussig is a member of the AML working group).
In addition we are looking at diagnostic approaches to IDH 1 and 2 mutation identification.
An initial comparison of 50 samples by three analysis methods will be conducted.
IDH1 and IDH2 variant discovery will first be performed using an established standard in house SOP (SOP: SMD103) for CE-SSCA
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •18 & Over Diagnosis of AML Generic Research consent given
Exclusion Criteria
- •Under 18 No generic research consent
Outcomes
Primary Outcomes
Pathology of Leukaemia cells
Time Frame: 15 years
Pathology of Leukaemia cells
Secondary Outcomes
No secondary outcomes reported